“Colchicine neither reduced the volume of effusions or prevented the occurrence of cardiac tamponade,” said study investigator Philippe Meurin, MD from Le centre de réadaptation cardiaque Les Grands Prés in Villeneuve Saint Denis, France.
“When you face a patient with a moderate to large post operative pericardial effusion, your attitude should be to not give him colchicine because the POPE-2 study shows it is useless, and not to give him non-steroidal anti-inflammatory drugs, because our earlier POPE-1 study showed that they are also useless.”
“POPE is a dangerous, yet asymptomatic condition for which there is still no known treatment,” he concluded. “Colchicine has been shown to be effective in other pericardial conditions – both the treatment of pericarditis, as well as the prevention of post-pericardotomy syndrome - so it was reasonable to explore its utility in treating POPE. But in the POPE-2 study, in which we had to screen over 8,000 individuals to identify 197 cases, colchicine was no better than placebo at reducing the effusion and the risk of cardiac tamponade.”
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved